- About Us
- Contact
- Editorial Staff
- Editorial Boards
- Advertise
- Do Not Sell My Information
- Terms & Conditions
- Privacy Policy
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
Mary Caffrey
Articles
Dr William Oh Discusses Goals of Prostate Cancer Awareness Month
September 26, 2022
Video
William Oh, MD, chief medical officer at Sema4 and a clinical professor of medicine at Mount Sinai, discusses Prostate Cancer Awareness Month and possible reasons for disparities in diagnoses and mortality in prostate cancer.
AACR Progress Report Highlights New Drugs Along With Disparities, Challenges of Obesity, Aging Population
September 23, 2022
Article
The annual report notes that progress in reducing cancer mortality is uneven among populations, with minority groups not seeing the same benefits from therapeutic advances. Cancers related to obesity are also on the rise.
Moonshot 2.0 Looks to Focus on Caregivers, Learn From Patients
September 21, 2022
Article
Danielle Carnival, PhD, addressed the National Comprehensive Cancer Network Policy Summit on Friday.
Recent NCCN Update Moves Zanubrutinib Ahead of Ibrutinib in CLL/SLL Based on Toxicity Profile
September 11, 2022
Article
The National Comprehensive Cancer Network recommendations come as the FDA weighs an indication in chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) for zanubrutinib.
Could CAR-NK Cells Using Cord Blood Offer a Treatment for Multiple Myeloma?
September 09, 2022
Article
For several years, investigators have examined the potential for allogenic natural killer (NK) cells as an alternative for “off-the-shelf” chimeric antigen receptor (CAR) treatments. New study results presented at the International Myeloma Society (IMS) meeting showed CD38 CAR-NK cells significantly reduced the tumor burden—and improved survival
Durvalumab With Chemo Wins FDA Approval in Treatment of Biliary Tract Cancers
September 06, 2022
Article
An estimated 1 in 4 patients treated with durvalumab and chemotherapy (gemcitabine plus cisplatin) was alive at 2 years compared with 1 in 10 treated with chemotherapy alone, with these results contributing to the FDA's approval of the first immunotherapy to treat these cancers.
Final Analysis of Phase 2 GRIFFIN Shows Daratumumab Improves PFS After 4 Years
August 27, 2022
Article
Patients receiving the quadruplet therapy have continued to show improved responses and higher rates of minimal residual disease (MRD) negativity.
SGLT2 Inhibitors, Combination Therapy Needed to Stem the Tide of CKD in Diabetes
August 20, 2022
Article
Katherine R. Tuttle, MD, FASN, FACP, FNKF, a nephrologist from the University of Washington and Providence Health Care, discussed new consensus guidelines that call for the early use of sodium glucose cotransporter 2 (SGLT2) inhibitors, GLP-1 receptor agonists, and finerenone in the care of patients with both chronic kidney disease (CKD) and diabetes.
Takeda Partnership With Xavier University Seeks Blueprint to Advance Health Equity
August 18, 2022
Article